Phase I Trial of Anti-CD19 Universal CAR-T Therapy For Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Latest Information Update: 17 Aug 2022
At a glance
- Drugs SC U02 (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 17 Aug 2022 New trial record